| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -3,785,321 | -2,859,264 |
| Proceeds from issuance of common stock, preferred stock, and/or pre-funded warrants, net of issuance costs | 3,456,228 | 3,456,228 |
| Net cash provided by financing activities | 3,456,228 | 3,456,228 |
| Net cash used in investing activities | - | 0 |
| Net decrease in cash, cash equivalents | -329,093 | 596,965 |
| Cash and cash equivalents at beginning of period | 2,184,863 | - |
| Cash and cash equivalents at end of period | 1,855,770 | - |
LIPELLA PHARMACEUTICALS INC. (LIPO)
LIPELLA PHARMACEUTICALS INC. (LIPO)